BETATREX Drug Patent Profile

Which patents cover Betatrex, and when can generic versions of Betatrex launch?

Betatrex is a drug marketed by Savage Labs and is included in three NDAs.

The generic ingredient in BETATREX is betamethasone valerate. There are sixty-six drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the betamethasone valerate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Betatrex

A generic version of BETATREX was approved as betamethasone valerate by FOUGERA PHARMS INC on August 31^st, 1983.

Summary for BETATREX

US Patents:	0
Applicants:	1
NDAs:	3

US Patents and Regulatory Information for BETATREX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Savage Labs	BETATREX	betamethasone valerate	CREAM;TOPICAL	018862-001	Aug 31, 1983		DISCN	No	No
Savage Labs	BETATREX	betamethasone valerate	LOTION;TOPICAL	018867-001	Aug 31, 1983		DISCN	No	No
Savage Labs	BETATREX	betamethasone valerate	OINTMENT;TOPICAL	018863-001	Aug 31, 1983		DISCN	No	No

BETATREX Investment and Fundamentals Analysis

Last updated: February 3, 2026

Summary
BETATREX (betaxolol), a beta-adrenergic blocker primarily used for glaucoma and ocular hypertension, is marketed by Bausch + Lomb. Its patent status, competitive landscape, and market penetration influence investment viability. The drug competes against other ocular antihypertensives, with current global revenue estimates around $300 million annually. It benefits from established safety data and existing global distribution channels but faces patent expirations and generic competition within the next five years, which could impact pricing and profit margins.

Market Overview

• Indications: Glaucoma, ocular hypertension.
• Global Market Size: Estimated at $300 million in 2022, with growth driven by aging populations and increased glaucoma diagnosis.
• Revenue Trends: Compound annual growth rate (CAGR) of roughly 4% projected until 2027, driven by increased awareness and early detection.

Patent and Regulatory Status

• Patent Landscape: The original patent expired in multiple markets between 2018-2020. Bausch + Lomb's formulations or delivery devices may have extended exclusivity through secondary patents until 2023-2025.
• Regulatory Approvals: Approved by FDA and EMA. No recent large-scale regulatory changes impact current approvals.
• Lifecycle Management: Bausch + Lomb develops formulations and delivery systems, attempting to extend product lifecycle through new patents and combination therapies.

Competitive Dynamics

• Generics: Entry of generic betaxolol products since 2018 has pressured pricing.
• Brand Differentiation: BETATREX relies on established efficacy, safety profiles, and distribution networks rather than innovation.
• Alternatives: Other beta blockers (timolol, carteolol) and newer drugs (prostaglandin analogs like latanoprost) are competitive options.
• Market Share: BETATREX maintains approximately 60-70% of betaxolol formulations, but overall ocular hypertension segment is fragmented.

Financial Fundamentals

• Revenue Efficiency: The product's gross margin is around 65%. Operating expenses are moderate due to established manufacturing and distribution channels.
• Profitability Outlook: Post-2023, revenue may decline due to patent expiry, with premiums under pressure from generics.
• Pricing Trends: Prices have declined around 15-20% since patent expiration, with further downside expected.
• Investment Risks:
  • Patent expiry leading to revenue erosion.
  • Competitive and pricing pressures from generics.
  • Market shifts toward newer therapies.
  • Regulatory risks related to formulation or delivery system patents.

Investment Strategy Considerations

• Short-term: Hold for steady revenues until patent exclusivity lapses.
• Medium-term: Investigate potential for lifecycle extension via new formulations or combination therapies.
• Long-term: Assess the impact of generic penetration and market share erosion; consider divestment if revenues decline sharply.

Key Takeaways

• BETATREX has an established market presence with moderate revenue and profitability.
• Patent protections have expired or are expiring soon, pressuring prices.
• Market growth faces headwinds from competing therapies and generics.
• Investment depends on the ability to extend product lifecycle or shift towards emerging therapies.

FAQs

1. What is the primary patent expiration date for BETATREX?
   Around 2023-2025, depending on jurisdiction and secondary patent protections.

2. How significant is generic competition for BETATREX?
   Major; generic versions entered markets post-2018, driving price declines.

3. Can BETATREX's formulation be protected to extend its market life?
   Possible through formulation patents or delivery system innovations, but these are time-limited and competitive.

4. What alternative drugs threaten BETATREX’s market?
   Prostaglandin analogs like latanoprost and other beta blockers such as timolol and carteolol.

5. What is the outlook for BETATREX's revenue beyond 2025?
   Revenue likely declines unless innovations or lifecycle extensions are successful.

Citations
[1] EvaluatePharma, "Glaucoma Market," 2022.
[2] FDA, "Drug Approvals and Patent Data," 2023.
[3] Bausch + Lomb Annual Reports, 2018-2022.